APA (7th ed.) Citation

Shen, L., Ananda, S., Cao, D., Han, C. H., Coward, J., Chao, Y., . . . Chiu, T. (2024). A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC). Journal of clinical oncology, 42(16_suppl), 4146. https://doi.org/10.1200/JCO.2024.42.16_suppl.4146

Chicago Style (17th ed.) Citation

Shen, Lin, et al. "A Phase II, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Pancreatic Ductal Adenocarcinoma (PDAC)." Journal of Clinical Oncology 42, no. 16_suppl (2024): 4146. https://doi.org/10.1200/JCO.2024.42.16_suppl.4146.

MLA (9th ed.) Citation

Shen, Lin, et al. "A Phase II, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (anti-PD-1 MAb) in Patients with Unresectable/metastatic Pancreatic Ductal Adenocarcinoma (PDAC)." Journal of Clinical Oncology, vol. 42, no. 16_suppl, 2024, p. 4146, https://doi.org/10.1200/JCO.2024.42.16_suppl.4146.